Abstract
The first potent selective small molecule inhibitor of a protein kinase was reported in 1994 by Parke- Davis. PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases. Subsequent structural elaboration of PD-153035 led to several 4-anilinoquinazolines that are currently in various stages of clinical trials for the treatment of kinase-mediated diseases. A homology model of EGFr with PD-153035 suggested that the 3-nitrogen atom of the quinazoline ring binds a water molecule. It was envisioned that this nitrogen atom could be replaced by a carbon atom containing an electron-withdrawing group. This critical observation by a group at Wyeth led to the identification of 4-(3- bromoanilino)-6,7-dimethoxy-3-quinolinecarbonitrile as an EGFr inhibitor. It was subsequently established that variation of the substituents on the 4-anilino group of the 6,7-dimethoxy-3-quinolinecarbonitrile changed the kinase specificity from EGFr to other kinases including Src and MEK. The 3-quinolinecarbonitrile template was also utilized to develop an irreversible inhibitor of EGFr, EKB-569, currently in clinical trials for the treatment of cancer. Further manipulation of the 3-quinolinecarbonitrile core provided tricyclic analogs, with the most potent kinase inhibitory activity observed with a benzo[g]quinoline-3-carbonitrile ring system. It was also found that 3-quinolinecarbonitriles with a 7-thiophene or phenyl substituent were potent Src kinase inhibitors.
Keywords: 4-Anilino-3-quinolinecarbonitriles, phenyl substituent, Src kinase inhibitors
Current Topics in Medicinal Chemistry
Title: 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors
Volume: 2 Issue: 9
Author(s): Diane H. Boschelli
Affiliation:
Keywords: 4-Anilino-3-quinolinecarbonitriles, phenyl substituent, Src kinase inhibitors
Abstract: The first potent selective small molecule inhibitor of a protein kinase was reported in 1994 by Parke- Davis. PD-153035, 4-(3-bromoanilino)-6,7-dimethoxyquinazoline, is an ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFr), with no appreciable inhibitory activity against several other kinases. Subsequent structural elaboration of PD-153035 led to several 4-anilinoquinazolines that are currently in various stages of clinical trials for the treatment of kinase-mediated diseases. A homology model of EGFr with PD-153035 suggested that the 3-nitrogen atom of the quinazoline ring binds a water molecule. It was envisioned that this nitrogen atom could be replaced by a carbon atom containing an electron-withdrawing group. This critical observation by a group at Wyeth led to the identification of 4-(3- bromoanilino)-6,7-dimethoxy-3-quinolinecarbonitrile as an EGFr inhibitor. It was subsequently established that variation of the substituents on the 4-anilino group of the 6,7-dimethoxy-3-quinolinecarbonitrile changed the kinase specificity from EGFr to other kinases including Src and MEK. The 3-quinolinecarbonitrile template was also utilized to develop an irreversible inhibitor of EGFr, EKB-569, currently in clinical trials for the treatment of cancer. Further manipulation of the 3-quinolinecarbonitrile core provided tricyclic analogs, with the most potent kinase inhibitory activity observed with a benzo[g]quinoline-3-carbonitrile ring system. It was also found that 3-quinolinecarbonitriles with a 7-thiophene or phenyl substituent were potent Src kinase inhibitors.
Export Options
About this article
Cite this article as:
Boschelli H. Diane, 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors, Current Topics in Medicinal Chemistry 2002; 2 (9) . https://dx.doi.org/10.2174/1568026023393354
DOI https://dx.doi.org/10.2174/1568026023393354 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives
Current Topics in Medicinal Chemistry Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease
Current Pharmaceutical Design Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Nifedipine Inhibits the Progression of An Experimentally Induced Cerebral Aneurysm in Rats with Associated Down-Regulation of NF-Kappa B Transcriptional Activity
Current Neurovascular Research A Novel Practical Synthesis of Pazopanib: An Anticancer Drug
Letters in Organic Chemistry The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design Nanotechnology approaches for pain therapy through transdermal drug delivery
Current Pharmaceutical Design Shedding Light on the Pathophysiology of Preeclampsia-Syndrome in the Era of Cardio-Obstetrics: Role of Inflammation and Endothelial Dysfunction
Current Hypertension Reviews P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-{1-(pentan-3-yl)-2- (thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido}hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist
Medicinal Chemistry TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics
Drug Metabolism Letters The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science